Bevacizumab Biosimilar Vial for Oncology from Japan
Avastin biosimilar bevacizumab, a VEGF monoclonal antibody in 100mg/4ml vials for retail infusion in cancer treatment, modulating angiogenesis via immune regulation. Fits HTS 3002.15.00.91 for MAB immunological products in measured doses.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Biosimilars need comparative efficacy data; FDA 351(k) pathway docs essential
• Use insulated packaging with data loggers for uninterrupted cold chain